Team

TGV-inhalonix is a privately held company and our goal is to revolutionize treatment and to bring the therapy of lung infections in Cystic Fibrosis patients to a principally new level of the efficacy.

Jeffrey A. Gelfand

Jeffrey A. Gelfand, MD, Ph.D

Dr. Jeffrey A. Gelfand, serves as a Chairman of the Scientific Advisory Board. Dr. Jeffrey A. Gelfand is a Professor and Chairman of the Department of Medicine at Tufts and Physician-in-Chief at the New England Medical center. He is currently an attending physician at Massachusetts General Hospital, a Clinical Professor at Harvard Medical School, and Professor of Medicine at Tufts. Dr. Gelfand conducts laboratory and clinical research in immunology, inflammation, infection, and tumor immunology.

  • 20 years of investment pharmaceutical R&D
  • Prior to joining TGV, Jeffrey was a Chief Scientific Officer & Founder Boston BioCom LLC, President of Pratt Medical Group
  • Over the last years, he has been increasingly active in the drug discovery and development
  • Manages the research at the M.G.H. (Massachusetts General Hospital) Research Center with an annual budget of over $600 mln
  • Jeffrey is a Clinical Professor, Department of Medicine, Harvard Medical School, member of AAAS

Sushant Kumar

Sushant Kumar, MD, Ph.D

Dr Sushant is responsible for the management of all operational aspects and investment.

  • Responsible for the management strategy and analysis
  • Over 12 years experience in healthcare research and investment management.

Michael Cynamon

Michael Cynamon, MD, Ph.D

Dr, Cynamon serves as a Member of Scientific Advisory Board. Dr. Michael Cynamon is an infectious disease specialist in Syracuse, New York and is affiliated with Syracuse Veterans Affairs Medical Center. He received his medical degree from Yale University School of Medicine and has been in practice for 43 years.He is a leading researcher in pulmonary infections with more than 35 years experience in healthcare research.

Worked in a tight collaboration with notable microbiologists George Tetz and Victor Tetz

Haran Schlamm, MD

Dr. Haran Schlamm, is a globally recognized infectious disease-trained physician. He has 20+ years pharmaceutical industry experience in clinical development and medical affairs seeking opportunities to support the development of novel anti-infective agents. Dr. Schlamm was the clinical lead for antifungals drugs to treat lung infections at Pfizer for 20+ years

Michelle Welborn

Dr. Michelle Welborn

Dr. Michelle Welborn, serves as a pharmaceutical consultant and provides regulatory consulting to manage the project in FDA. Michelle Welborn holds a Doctor of Pharmacy degree from Campbell University School of Pharmacy. Michelle has 15 years experience in pharmaceuticals as a liaison in Medical and Regulatory Affairs for both Astra-Merck and Sanofi –Aventis Pharmaceuticals, and as Clinical Pharmacy Manager for a Health Maintenance Organization (HMO) , and as a Pharmacy Practice resident at Wake Forest University Baptist Medical CenterShe has participated in workshops and consortiums organized by the NIH (National Institutes of Health), the National Organization of Rare Diseases (NORD), the International Congress of Rare Diseases (ICORD), and the Centers for Disease Control (CDC), the Epilepsy Foundation of America, and the Australian Dravet syndrome Family Day. She served for two years as the Professional Advisory Board Chair for the IDEA League before founding ICE. She currently serves on the Professional Advisory Boards for the Charlie Foundation and Lennox-Gastaut Syndrome Foundation.